- Home
- ANAB vs URG Comparison
ANAB vs URG Comparison
Compare ANAB & URG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- URG
- Stock Information
- Founded
- ANAB 2005
- URG 2004
- Country
- ANAB United States
- URG United States
- Employees
- ANAB N/A
- URG N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- URG Precious Metals
- Sector
- ANAB Health Care
- URG Basic Materials
- Exchange
- ANAB Nasdaq
- URG Nasdaq
- Market Cap
- ANAB 630.2M
- URG 565.5M
- IPO Year
- ANAB 2017
- URG N/A
- Fundamental
- Price
- ANAB $21.08
- URG $1.51
- Analyst Decision
- ANAB Buy
- URG Strong Buy
- Analyst Count
- ANAB 10
- URG 3
- Target Price
- ANAB $48.00
- URG $2.63
- AVG Volume (30 Days)
- ANAB 515.2K
- URG 6.9M
- Earning Date
- ANAB 11-04-2025
- URG 11-05-2025
- Dividend Yield
- ANAB N/A
- URG N/A
- EPS Growth
- ANAB N/A
- URG N/A
- EPS
- ANAB N/A
- URG N/A
- Revenue
- ANAB $123,164,000.00
- URG $39,488,000.00
- Revenue This Year
- ANAB $11.40
- URG N/A
- Revenue Next Year
- ANAB $8.17
- URG $232.02
- P/E Ratio
- ANAB N/A
- URG N/A
- Revenue Growth
- ANAB 304.17
- URG 149.20
- 52 Week Low
- ANAB $12.21
- URG $0.55
- 52 Week High
- ANAB $39.50
- URG $1.62
- Technical
- Relative Strength Index (RSI)
- ANAB 47.97
- URG 59.60
- Support Level
- ANAB $17.11
- URG $1.47
- Resistance Level
- ANAB $24.07
- URG $1.60
- Average True Range (ATR)
- ANAB 1.49
- URG 0.08
- MACD
- ANAB -0.03
- URG -0.00
- Stochastic Oscillator
- ANAB 57.03
- URG 60.34
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About URG Ur Energy Inc (Canada)
Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.